Business, energy, technology, markets and global industry news from Business News Today

Haisco Pharmaceutical Group

PharmaDeviceNews Haisco Pharmaceutical Group
Representative image: Laboratory researchers assess an oral blood disorder therapy as Nuvectis Pharma’s ciprocopan secures China approval for treatment-naive paroxysmal nocturnal hemoglobinuria.
Pharma & Biotech

Ciprocopan China approval gives PNH patients a new once-daily oral Factor B treatment option

Nuvectis Pharma’s ciprocopan wins China approval for PNH. Read how the once-daily Factor B drug could reshape the global treatment race.

Read More
Representative image of pharmaceutical executives and scientists reviewing drug discovery data in a modern research setting, reflecting Eli Lilly and Haisco Pharmaceutical’s multi-program collaboration and the growing role of China-originated innovation in global pharma licensing.
Pharma & Biotech

Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?

Eli Lilly’s Haisco deal could be worth over $3 billion. Find out why China-originated drug discovery is becoming harder to ignore.

Read More
Pharma & Biotech

AirNexis launches with $200m and Phase 2 dual PDE3/4 COPD drug licensed from Haisco

AirNexis launches with $200M and ex-China rights to AN01. Find out why this dual-pathway COPD therapy is drawing investor attention in 2026.

Read More